var data={"title":"Sulfur hexafluoride lipid microspheres: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sulfur hexafluoride lipid microspheres: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/759210?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26147211\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiopulmonary reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26419190\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lumason</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625115\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>SonoVue</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26147293\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26418825\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiovascular imaging:</b> IV: 2 mL during echocardiography; may repeat once during procedure to prolong contrast enhancement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Adjust the mechanical index for the ultrasound device to 0.8 or lower after baseline noncontrast echocardiography is complete. Continue imaging following injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic ultrasonography:</b> IV: 2.4 mL during ultrasonography; may repeat once during procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Adjust to low mechanical index (&le;0.4) after identification of the target focal lesion on non-contrast ultrasound examination. Continue imaging following injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic vessel assessment:</b> SonoVue [Canadian product]: IV: 1.2 mL during Doppler ultrasound; may repeat once during procedure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46562159\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic ultrasonography:</b> Children and Adolescents: IV: 0.03 mL/kg during ultrasonography; may repeat once during procedure. Maximum: 2.4 mL/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Adjust to low mechanical index (&le;0.4) after identification of the target focal lesion on non-contrast ultrasound examination. Continue imaging following injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary ultrasonography:</b> Infants, Children, and Adolescents: Intravesical: 1 mL during ultrasonography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>Adjust to low mechanical index (&le;0.4) after baseline non-contrast ultrasound examination. Perform continuous alternate ultrasound imaging of the bladder, ureters, and kidneys during filling and voiding of the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26418826\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26418827\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26418828\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46100862\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lumason: Lipid-type A 25 mg and sulfur hexafluoride 60.7 mg (1 ea) [contains polyethylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46100861\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625116\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension Reconstituted, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SonoVue: Lyophilized powder with lipids 25 mg and sulfur hexafluoride ~58 mg (1 ea) [contains polyethylene glycol; final reconstituted product contains sulfur hexafluoride ~48 mcg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26418830\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as an IV bolus; do not administer intra-arterially. Follow each injection with an intravenous flush of NS (5 mL in adults).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SonoVue [Canadian product]: Administer as an IV bolus; do not administer intra-arterially. The recommended rate of injection during Doppler ultrasound is 1.2 mL over a period of 1 second; however, a slower rate of injection over 2 to 3 seconds is recommended during transcranial Doppler to reduce blooming artifacts. Follow each injection with an intravenous flush of 5 mL NS.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravesical: Empty the bladder of urine, and then fill bladder with NS to ~33% to 50% of predicted total volume. Administer sulfur hexafluoride lipid microspheres as an intravesical bolus injection through a 6 to 8 french urinary catheter. Continue filling bladder with NS until patient has the urge to micturate or at first sign of back pressure. Immediately following the first voiding, the bladder may be refilled with NS only for a second cycle of voiding and imaging.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26147295\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiovascular imaging:</b> To opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adults with suboptimal echocardiograms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic ultrasonography:</b> To characterize focal liver lesions in adults and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract ultrasonography:</b> Evaluation of suspected or known vesicoureteral reflux in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>SonoVue [Canadian product]:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiovascular imaging:</b> To improve the visualization of cardiac chambers and endocardial border delineation during echocardiography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic vessel assessment:</b> To facilitate Doppler evaluation of cerebral and extracranial carotid and peripheral arteries; increases Doppler image quality and the duration of clinically useful signal enhancement in abdominal and renal arteries and in portal vein assessment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Limitations of use:</i> Use only in patients whose examinations without contrast enhancement are inconclusive.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26641828\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, bradycardia, cardiac arrest, flushing, hypertension, hypotension, ischemia, shock, supraventricular tachycardia, syncope, tachycardia, ventricular fibrillation, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Convulsions, loss of consciousness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactic shock, anaphylactoid reaction, anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea, hypoxia, pharyngeal edema, respiratory distress, stridor, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% postmarketing, and/or case reports: Cardiac arrhythmia, chest discomfort, chest pain, dysgeusia, feeling hot, headache, hypertensive crisis, nausea, pain at injection site, warm sensation at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26147296\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sulfur hexafluoride lipid-type A microspheres or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SonoVue [Canadian product]: Hypersensitivity to sulfur hexafluoride or any component of the formulation; known right-to-left cardiac shunts; severe pulmonary hypertension (pulmonary artery pressure &gt;90 mm Hg); uncontrolled systemic hypertension; adult respiratory distress syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26416885\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiopulmonary reactions: <b>[US Boxed Warning]:</b> <b>Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.</b> Risk is increased in patients with unstable cardiopulmonary conditions (acute MI, acute coronary artery syndromes, worsening or unstable CHF, serious ventricular arrhythmias). Monitor all patients for acute reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including skin erythema, rash, urticaria, flushing, throat tightness, dyspnea, or anaphylactic shock may occur (uncommon). Immediate treatment for hypersensitivity reactions should be available during use. Monitor all patients for acute reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For IV or intravesical use only; do not administer intra-arterially.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; High mechanical index values: Not recommended for use at mechanical indices &gt;0.8. High mechanical index values may cause microsphere cavitation or rupture and lead to ventricular arrhythmias; end-systolic triggering with high mechanical indices has also been reported to cause ventricular arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic embolization: After administration to patients with  cardiac shunts, some IV injected sulfur hexafluoride lipid-type A microspheres may bypass filtering by the lung and enter the arterial circulation. Assess patients with shunts for embolic phenomena following administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26189976\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26189973\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=97563&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26416882\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26416884\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sulfur hexafluoride lipid-type A microspheres is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother. Sulfur hexafluoride is rapidly cleared. Prior to breast-feeding, women should pump and discard breast milk one time after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26418833\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiopulmonary reactions; cardiac rhythm monitoring; signs and symptoms of anaphylactoid reactions; heart rate, respiratory rate, and pulse oximetry (during and for 30 minutes following infusion); assess patients with cardiac shunts for embolic phenomena following administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26416889\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ultrasound contrast agent for cardiovascular imaging and hepatic and urinary tract ultrasonography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26416891\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Cardiovascular imaging 1.7 to 3.1 minutes (useful contrast effect)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Sulfur hexafluoride (SF<sub>6</sub>): 341 L (0.03 mL/kg dose); 710 L (0.3 mL/kg dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Little or none</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: SF<sub>6</sub>: ~10 minutes (0.3 mL/kg dose; half-life could not be estimated at the 0.03 mL/kg dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SF<sub>6</sub>: 1 to 2 minutes; up to 4 minutes in pulmonary impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: SF<sub>6</sub>: Lungs (88% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46251918\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Lumason Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60.7-25 mg (1): $174.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26531305\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>SonoVue (AT, BE, CH, CN, CY, CZ, DE, EE, ES, FR, GR, HR, HU, IE, IL, IT, KR, LT, LU, MT, PL, PT, RO, SE, SG, SI, SK, TR);</li>\n      <li>SonoVUe (DK, FI, NL, NO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Lumason (sulfur hexafluoride lipid-type A microspheres) [prescribing information]. Monroe Twp., NJ: Bracco Diagnostics; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SonoVue (sulfur hexafluoride) [product monograph]. Montreal, Quebec, Canada: Bracco Imaging Canada; December 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 97563 Version 30.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26147211\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26419190\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50625115\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F26147293\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26418825\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46562159\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F26418826\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26418827\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26418828\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46100862\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46100861\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50625116\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26418830\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26147295\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F26641828\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26147296\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26416885\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26189976\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F26189973\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26416882\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26416884\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26418833\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26416889\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F26416891\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46251918\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26531305\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/97563|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}